Sage Therapeutics to cut about 188 jobs after depression drug setback
(Reuters) -Sage Therapeutics said on Thursday it plans to lay off about 188 people, or about 40% of its workforce, weeks after the U.S. health regulator declined to approve its…
(Reuters) -Sage Therapeutics said on Thursday it plans to lay off about 188 people, or about 40% of its workforce, weeks after the U.S. health regulator declined to approve its…
(Reuters) – Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies…
By Carolina Mandl NEW YORK (Reuters) – Soros Fund Management, the family office of billionaire George Soros, added to its portfolio new shares in financial and healthcare companies and a…
By Sriparna Roy and Khushi Mandowara (Reuters) – TG Therapeutics Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms…
Objective: to clinically validate efficacy of a new form of immunotherapy utilizing CAR-T cells to target multiple difficult-to-treat tumors PARIS, June 13, 2022 — Mnemo Therapeutics, a biotechnology company developing…
Global biopharmaceutical leader relocating to premier New Jersey campus owned by Rubenstein Partners and Vision Real Estate Partners WARREN, N.J., June 10, 2022 — Rubenstein Partners, L.P. (including its affiliates, Rubenstein),…
“In the past year, Cytovia has graduated into a fully-integrated global biotech with R&D and cell manufacturing capabilities. As we advance our product candidates towards clinical trials and prepare to become…
BEDMINSTER, N.J., 3 juin 2022 — Jubilant Therapeutics Inc., une société de thérapies de précision au stade clinique qui fait progresser les petites molécules thérapeutiques pour répondre à des besoins…
BEDMINSTER, N.J., 3 juin 2022 — Jubilant Therapeutics Inc., une société de thérapies de précision au stade clinique qui fait progresser les petites molécules thérapeutiques pour répondre à des besoins…
BEDMINSTER, N.J., 3. Juni 2022 — Jubilant Therapeutics Inc., ein Unternehmen für Präzisionstherapeutika in der klinischen Phase, das niedermolekulare Therapeutika für ungedeckten medizinischen Bedarf in der Onkologie und bei Autoimmunerkrankungen…
(Reuters) -The U.S. Food and Drug Administration said on Wednesday it has withdrawn its approval for TG Therapeutics Inc’s lymphatic cancer treatment Ukoniq over concerns of higher risk of death…
Le JBI-802 est le premier inhibiteur équipotent double de LSD1 et HDAC6, administré par voie orale Le JBI-802 a démontré une activité anti-tumorale synergique dans les modèles animaux BEDMINSTER, N.J.,…
JBI-802 ist der erste oral verabreichte, duale äquipotente Hemmstoff von LSD1 und HDAC6 JBI-802 zeigte synergistische Anti-Tumor-Aktivität in Tiermodellen BEDMINSTER, N.J., 27. April 2022 — Jubilant Therapeutics Inc., ein biopharmazeutisches…